Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALASCCA ASA in PI3K-mutant colorectal cancer
2024-513778-23-00Phase 3Authorised
- Sponsor
- Karolinska Institutet
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in colorectal cancer (CRC) comparing Acetylsalicylic acid (Trombyl) with Placebo (2 arms). Primary endpoint: Time to recurrence at 3 years in PIK3CA exon 9/20-mutated tumors. Planned start Oct 2024; status: authorised.
02
Drugs
aspirin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-513778-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513778-23-00.